Update on the status of DP2 receptor antagonists; From proof of concept through clinical failures to promising new drugs

Expert Opinion on Investigational Drugs

Volumn 23, Issue 1, 2014, Pages 55-66

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

ADC 3680; ARRY 502; Asthma; BI 671800; DP1 receptor; DP2 receptor; Eosinophil; Inflammation; MK 1029; OC 459; PGD2; Setipiprant; Vidupiprant

Indexed keywords

ADC 3680; AM 211; AM 461; ARRY 502; ASP 5642; ATX 2417; AZD 1981; AZD 5985; AZD 8075; BI 144807; BI 671800; CETIRIZINE; CORTICOSTEROID; FLUTICASONE PROPIONATE; KETOCONAZOLE; MK 1029; MK 7246; MOMETASONE FUROATE; MONTELUKAST; NEW DRUG; OC 459; ONO 4053; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; QAV 680; QAW 039; RG 7185; SETIPIPRANT; TM 30089; UNCLASSIFIED DRUG; VIDUPIPRANT;

ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG LEGISLATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIC ESOPHAGITIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; HAY FEVER; IC 50; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TH2 CELL; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTI-ALLERGIC AGENTS; HUMANS; HYPERSENSITIVITY; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

EID: 84889841360     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.839658     Document Type: Review

References (67)

1. Needleman P. Characterization of the reaction sequence involved in phospholipid labeling and deacylation and prostaglandin synthesis and actions. J Allergy Clin Immunol 1978;62(2):96-102 (Pubitemid 9003161)
2. Wenzel SE, Westcott JY, Smith HR, Larsen GL. Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups. An alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. Am Rev Respir Dis 1989;139(2):450-7 (Pubitemid 19057424)
3. Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 2011;63(3):471-538
4. Giles H, Leff P, Bolofo ML, et al. The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective, and potent competitive antagonist. Br J Pharmacol 1989;96:291-300 (Pubitemid 19045102)
5. McKenniff MG, Rodger IW, Norman P, Gardiner PJ. Characterisation of receptors mediating the contractile effects of prostanoids in guinea-pig and human airways. Eur J Pharmacol 1988;153(2-3):149-59
6. Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193(2):255-61 (Pubitemid 32524457)
7. Sawyer N, Cauchon E, Chateauneuf A, et al. Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol 2002;137(8):1163-72 (Pubitemid 36071733)
8. Nagata K, Hirai H. The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids 2003;69(2-3):169-77 (Pubitemid 36976172)
9. Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007;6(4):313-25 (Pubitemid 46505882)
10. Sugimoto H, Shichijo M, Iino T, et al. An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 2003;305(1):347-52 (Pubitemid 36373870)
11. McKenniff MG, Norman P, Cuthbert NJ, Gardiner PJ. BAY u3405, a potent and selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro. Br J Pharmacol 1991;104(3):585-90
12. Magnussen H, Boerger S, Templin K, Baunack AR. Effects of a thromboxane-receptor antagonist, BAY u 3405, on prostaglandin D2-and exercise-induced bronchoconstriction. J Allergy Clin Immunol 1992;89(6):1119-26
13. Ly TW, Bacon KB. Small-molecule CRTH2 antagonists for the treatment of allergic inflammation: an overview. Expert Opin Investig Drugs 2005;14(7):769-73 (Pubitemid 41030945)
14. Norman P. DP2 Receptor Antagonists in Development. Expert Opin Investig Drugs 2010;19(8):947-61
15. Pettipher R, Whittaker M. Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis. J Med Chem 2012;55(7):2915-31
16. Lamers C, Flesch D, Schubert-Zsilavecz M, Merk D. Novel prostaglandin receptor modulators: a patent review (2002-2012)-part I: non-EP receptor modulators. Expert Opin Ther Pat 2013;23(1):47-77
17. Hall I, Sarno M, Diss B, et al. Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid. European Resp J 2012;P1792
18. Sutherland R, Tetzlaff K, Nivens C, et al. Efficacy and safety of BI 671800, an oral CRTH2 antagonist in controller näve patients with poorly-controlled asthma. European Resp J 2012;P3084
19. Fowler A, Miller C, LaForce D, et al. Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid. European Resp J 2012;P3085
20. Krug N, Gupta A, Badorrek D, et al. CRTH2 Antagonist, BI 671800 (BI), reduces nasal symptoms and inhibits nasal cytokines and eosinophils in SAR patients exposed to grass pollen in an environmental challenge chamber (ECC). Am J Resp Crit Care Med 2012;185:A4185
21. Islam SA, Luster AD. T cell homing to epithelial barriers in allergic disease. Nat Med 2012;18(5):705-15
22. Wang YH, Trucksis M, McElwee JJ, et al. UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study. Clin Pharmacol Ther 2012;92(1):96-102
23. Merck Sharp and Dohme Corp, Indole Derivatives as CRTH2 receptor antagonists. US-8394819; 2013
24. Simard D, Leblanc Y, Berthelette C, et al. Azaindoles as potent CRTH2 receptor antagonists. Bioorg Med Chem Lett 2011;21(2):841-5
25. Fitzgerald MF, Whitmarsh M, Prosser J, et al. The In Vitro Profile Of ADC3680, A Potent And Selective CRTh2 Antagonist For The Treatment Of Inadequately Controlled Asthma. Am J Resp Crit Care Med 2013;187:A2617
26. Fitzgerald MF, Snape S, Febrarro S, et al. The safety, PK and PD Profile Of ADC3680, a potent and selective CRTh2 Antagonist, in healthy volunteers and partly controlled atopic asthmatic subjects. Am J Resp Crit Care Med 2013;187:A3874
27. Research Ethics Service. A Study of 14C-ADC3680 in Healthy Volunteers. 11/WA/0324 2011. Avaiolable from http://www.nres.nhs.uk/researchsummaries/ entryid29=137794&q=0~adc3680
28. Pettipher R, Vinall SL, Xue L, et al. Pharmacologic profile of OC000459, a Potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T Helper 2 Lymphocytes and Eosinophils. J Pharmacol Exp Ther 2012;340(2):473-82
29. Barnes N, Pavord I, Chuchalin A, et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 2012;42(1):38-48
30. Singh D, Cadden P, Hunter M, et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J 2013;41(1):46-52
31. Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy 2012;67(12):1572-9
32. Array BioPharma. ARRY-502 Meets primary and key secondary endpoints in asthma study. Available from: http://phx. corporate-ir.net/phoenix.zhtml c=123810&p=irolnewsArticle& ID=1839862 [Last accessed 23 July 2013]
33. Straumann A, Hoesli S, Bussmann Ch, et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 2013;68(3):375-85
34. Array Biopharma Inc. 4-Heteroaryl-substituted phenoxyphenylacetic acid WO-2009061730 (2009)
35. Burgess L, Anderson C, Nugent N, et al. Safety, PK and PD of ARRY-502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies. Inflamm Res 2010;59(suppl 3):S287
36. Bell S, Anderson L, Nugent C, et al. Safety, PK and PD of ARRY-502, a CRTh2 Antagonist, in healthy subjects with a history of seasonal allergies. Eur Resp J 2010;36(suppl):708s
37. Chantry D, Ono J, Eberhardt C, et al. The Signature Selection Strategies for CRTh2 Antagonists: baseline Characteristics of a Mild to Moderate Persistent Asthma Population. Am J Resp Crit Care Med 2013;187:A1339
38. Bain G, Lorrain DS, Stebbins KJ, et al. Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation. J Pharmacol Exp Ther 2011;338(1):290-301
39. Bain G, King CD, Brittain J, et al. Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type. J Clin Pharmacol 2012;52(10):1482-93
40. Norman P. A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033. Expert Opin Ther Pat 2011;21(12):1931-6
41. Amira Pharmaceuticals Inc, DP2 receptor antagonist and uses thereof, WO-2011085033 (2011)
42. Ulven T, Kostenis E. Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J Med Chem 2005;48(4):897-900 (Pubitemid 40270433)
43. Grimstrup M, Receveur JM, Rist O, et al. Exploration of SAR features by modifications of thiazoleacetic acids as CRTH2 antagonists. Bioorg Med Chem Lett 2010;20(5):1638-41
44. Ito S, Terasaka T, Zenkoh T, et al. Discovery of novel and potent CRTH2 antagonists. Bioorg Med Chem Lett 2012;22(2):1194-7
45. Tasaki M, Kobayashi M, Tenda Y, et al. Inhibition of antigen-induced airway inflammation and hyperresponsiveness in guinea pigs by a selective antagonist of "chemoattractant receptor homologous molecule expressed on Th2 cells" (CRTH2). Eur J Pharm Sci 2013;49(3):434-40
46. Yoshida S, Yoshino T, Miyafuji M, et al. Development of a practical and scalable synthesis of a potent CRTH2 antagonist. Org. Process Res. Dev 2012;16(9):1544-51
47. Snell N, Foster M, Vestbo J. Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD. Respir Med 2013;pii:S0954-6111
48. Schmidt JA, Bell FM, Akam E, et al. Biochemical and pharmacological characterization of AZD1981, an orally available selective DP2 antagonist in clinical development for asthma. Br J Pharmacol 2013;168(7):1626-38
49. AstraZeneca plc, AZD1981. Available from: http://www.ncats.nih.gov/files/ AZD1981.pdf
50. AstraZeneca plc, A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled,Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of AZD8075 in Healthy Male Volunteers, Clinical Study Report, September 2009
51. AstraZeneca plc, A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of AZD5985 in Healthy Male Subjects, Clinical Study Report, December 2009
52. Fretz H, Valdenaire A, Pothier J, et al. Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b] indol-5(2H)-yl)acetic acid (Setipiprant/ACT-129968), a Potent, selective and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist. J Med Chem 2013;56(12):4899-911
53. Valdenaire A, Pothier J, Renneberg D, et al. Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold. Bioorg Med Chem Lett 2013;23(4):944-8
54. Actelion AG. Actelion's Novel Crth2 Antagonist Meets Primary Endpoint In Phase II Study In Patients With Seasonal Allergic Rhinitis, Press Release, 23 may 2011
55. Liu J, Li A.-R, Wang Y, et al. Discovery of AMG 853, a CRTH2 and DP Dual Antagonist. ACS Med. Chem Lett 2011;2:326-30
56. Foti RS, Pearson JT, Wong SL, et al. Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors. Drug Metab Dispos 2012;40(12):2239-49
57. Busse WW, Wenzel SE, Meltzer EO, et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol 2013;131(2):339-45
58. Wang Y, Fu Z, Schmitt M, et al. Optimization of phenylacetic acid derivatives for CRTH2 and DP selective antagonism. Bioorg Med Chem Lett 2012;22(1):367-70
59. Novartis AG. A randomized, double-blind, parallel group study to compare the pharmacodynamics/efficacy, safety and pharmacokinetics of QAV680 versus placebo in patients with moderate persistent asthma. July 2012.Available from: http://www. novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do trialResult=6683
60. Novartis AG. A randomized, double-blind, double-dummy, placebo-controlled three-period incomplete cross over study to compare the effect of combined treatment with QAV680 and cetirizine on total nasal symptom score in allergic rhinitis patients in an environmental exposure chamber. March 2012. Available from: http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do trialResult=4660)
61. Sandham DA, Discovery of novel CRTh2 receptor antagonists for treatment of allergic diseases, at 4th RSC-SCI GPCR Meeting, 17-19th September 2012
62. F. Hoffmann-La Roche AG, Napthylacetic acids. WO2010055004; 2010
63. Gallant M, Beaulieu C, Berthelette C, et al. Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg Med Chem Lett 2011;21(1):288-93
64. Molinaro C, Bulger PG, Lee EE, et al. CRTH2 antagonist MK-7246: a synthetic evolution from discovery through development. J Org Chem 2012;77(5):2299-309
65. Gervais FG, Sawyer N, Stocco R, et al. Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist. Mol Pharmacol 2011;79(1):69-76
66. Mauser PJ, House A, Jones H, et al. Pharmacological characterization of the late phase reduction in lung functions and correlations with microvascular leakage and lung edema in allergen-challenged Brown Norway rats. Pulm Pharmacol Ther 2013;doi:pii: S1094-5539(13)00079-5. 10.1016/
67. Andrés M, Bravo M, Buil MA, et al. 2-(1H-Pyrazol-4-yl)acetic acids as CRTh2 antagonists. Bioorg Med Chem Lett 2013;23(11):3349-53